The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Diagnostic Value of Anti-Müllerian Hormone as a Biomarker for Polycystic Ovary Syndrome: A Meta-Analysis Update
Abstract
Objective: A previous meta-analysis carried out on the predictive ability of anti-Müllerian hormone (AMH) for polycystic ovary syndrome (PCOS) showed that independent AMH may be a useful initial diagnostic test for PCOS. The aims of this study were to update the meta-analysis and to evaluate the diagnostic efficacy of AMH when it replaces polycystic ovary morphology (PCOM) in the Rotterdam criteria. Methods: Two independent reviewers searched PubMed, Cochrane Library, and the Web of Science databases systematically to identify relevant articles by using the key words "anti-Müllerian hormone" and "polycystic ovary syndrome." The deadline for manuscript inclusion was July 31, 2018. A random effects model was used and subgroup analysis and meta regression were performed to identify possible sources of heterogeneity. The methodologic quality of each study was assessed by QUADAS-2 and funnel plot asymmetry test. Results: According to the inclusion criteria, 29 studies were included in this meta-analysis. The pooled sensitivity, specificity, and diagnostic odds ratio (DOR) for AMH alone detecting PCOS were 0.76 (95% confidence interval [CI] 0.71 to 0.81), 0.86 (95% CI 0.82 to 0.90) and 20 (95% CI 12 to 33), respectively. When AMH replaces polycystic ovary morphology (PCOM) for the diagnosis of PCOS, the pooled sensitivity, specificity, and DOR rose to 0.93 (95% CI 0.89 to 0.96), 0.99 (95% CI 0.95 to 1.00), and 1,634 (95% CI 217 to 12,324), respectively. The area under the summary r…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The characteristic arrest of antral follicular development in PCOS results in high AMH (Zhao et al., 2019).”
From Endometriosis and polycystic ovary syndrome are diametric disorders (2021) · cites this paper as Zhao et al., 2019
Citations
Cites
QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies
Whiting, P. F., Rutjes, A. W. S., Westwood, M. E., Mallett, S., Deeks, J. J., Reitsma, J. B., Leeflang, M. M. G., Sterne, J. A. C., Bossuyt, P. M. M., & the QUADAS-2 Group* (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-8-201110180-00009 · Cited by 14,199
Balen, A. H., Morley, L. C., Misso, M., Franks, S., Legro, R. S., Wijeyaratne, C. N., Stener-Victorin, E., Fauser, B. C. J. M., Norman, R. J., & Teede, H. (2016) · Human Reproduction Update · doi:10.1093/humupd/dmw025 · Cited by 705
Research works printed but not linked: 23
- Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, 2008, Consensus on infertility treatment related to polycystic ovary syndrome, Fertil Steril, 89, 505, 10.1016/j.fertnstert.2007.09.041 · DOI
- Patel, 2018, Polycystic ovary syndrome (PCOS), an inflammatory, systemic, lifestyle endocrinopathy, J Steroid Biochem Mol Biol, 182, 27, 10.1016/j.jsbmb.2018.04.008 · DOI · Paper page
- Siow, 2005, Serum mullerian-inhibiting substance levels in adolescent girls with normal menstrual cycles or with polycystic ovary syndrome, Fertil Steril, 84, 938, 10.1016/j.fertnstert.2005.02.052 · DOI
- Bhide, 2016, Anti-Müllerian hormone and polycystic ovary syndrome, Best Pract Res Clin Obstet Gynaecol, 37, 38, 10.1016/j.bpobgyn.2016.03.004 · DOI
- Madnani, 2013, Polycystic ovarian syndrome, Indian J Dermatol Venereol Leprol, 79, 310, 10.4103/0378-6323.110759 · DOI
- Escobar-Morreale, 2018, Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment, Nat Rev Endocrinol, 14, 270, 10.1038/nrendo.2018.24 · DOI · Paper page
- Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, 2004, Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome, Fertil Steril, 81, 19, 10.1016/j.fertnstert.2003.10.004 · DOI · Paper page
- Azziz, 2009, The androgen excess and PCOS society criteria for the polycystic ovary syndrome: the complete task force report, Fertil Steril, 91, 456, 10.1016/j.fertnstert.2008.06.035 · DOI · Paper page
- Balen, 2003, Ultrasound assessment of the polycystic ovary: international consensus definitions, Hum Reprod Update, 9, 505, 10.1093/humupd/dmg044 · DOI · Paper page
- Dewailly, 2014, Using cluster analysis to identify a homogeneous subpopulation of women with polycystic ovarian morphology in a population of non-hyper-androgenic women with regular menstrual cycles, Hum Reprod, 29, 2536, 10.1093/humrep/deu242 · DOI
- Dewailly, 2010, Reconciling the definitions of polycystic ovary syndrome: the ovarian follicle number and serum anti-Mullerian hormone concentrations aggregate with the markers of hyperandrogenism, Journal Clin Endocrinol Metab, 95, 4399, 10.1210/jc.2010-0334 · DOI
- Rey, 2003, AMH/MIS: what we know already about the gene, the protein and its regulation, Mol Cell Endocrinol, 211, 21, 10.1016/j.mce.2003.09.007 · DOI
- Peluso, 2014, AMH: an ovarian reserve biomarker in assisted reproduction, Clin Chim Acta, 437, 175, 10.1016/j.cca.2014.07.029 · DOI
- Weenen, 2004, Anti-Mullerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment, Mol Hum Reprod, 10, 77, 10.1093/molehr/gah015 · DOI
- Sahmay, 2013, Serum anti-Mullerian hormone levels in the main phenotypes of polycystic ovary syndrome, Eur J Obstet Gynecol Reprod Biol, 170, 157, 10.1016/j.ejogrb.2013.05.019 · DOI
- Dewailly, 2014, The physiology and clinical utility of anti-Mullerian hormone in women, Hum Reprod Update, 20, 370, 10.1093/humupd/dmt062 · DOI
- Bersinger, 2007, Measurement of anti-mullerian hormone by Beckman Coulter ELISA and DSL ELISA in assisted reproduction: differences between serum and follicular fluid, Clin Chim Acta, 384, 174, 10.1016/j.cca.2007.05.011 · DOI
- Gassner, 2014, First fully automated immunoassay for anti-Mullerian hormone, Clin Chem Lab Med, 52, 1143, 10.1515/cclm-2014-0022 · DOI
- Li, 2010, Elevated serum anti-mullerian hormone in adolescent and young adult Chinese patients with polycystic ovary syndrome, Wien Klin Wochenschr, 122, 519, 10.1007/s00508-010-1426-x · DOI
- Dewailly, 2011, Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries, Hum Reprod, 26, 3123, 10.1093/humrep/der297 · DOI
- Iliodromiti, 2013, Can anti-Mullerian hormone predict the diagnosis of polycystic ovary syndrome? A systematic review and meta-analysis of extracted data, J Clin Endocrinol Metab, 98, 3332, 10.1210/jc.2013-1393 · DOI
- Hyldgaard, 2015, Comparison of two different methods for measuring anti-mullerian hormone in a clinical series, Reprod Biol Endocrinol, 13, 107, 10.1186/s12958-015-0101-5 · DOI
- Lie Fong, 2012, Serum anti-mullerian hormone levels in healthy females: a nomogram ranging from infancy to adulthood, J Clin Endocrinol Metab, 97, 4650, 10.1210/jc.2012-1440 · DOI
Cited by
Endometriosis and polycystic ovary syndrome are diametric disorders
Dinsdale, N. L., & Crespi, B. J. (2021) · Evolutionary Applications · doi:10.1111/eva.13244 · Cited by 90
“3.2.2 | Anti- Müllerian hormone AMH regulates sex- specific early development and mediates ovarian reserve (Barbotin et al., 2019; Lv et al., 2020).”
BackgroundInfluentialIwase, A., Hasegawa, Y., Tsukui, Y., Kobayashi, M., Hiraishi, H., Nakazato, T., & Kitahara, Y. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1273966 · Cited by 55
“Although meta-analyses have con fi rmed that women with PCOS of all ages have higher AMH values than age-matched control women (38, 39), it is dif fi cult to establish a universal AMH cut-off because AMH levels decline in an age-dependent manner (40).”
BackgroundZhang, X., Liang, B., Zhang, J., Hao, X., Xu, X., Chang, H., Leung, P. C. K., & Tan, J. (2021) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2020.111139 · Cited by 64
The Role of Serum Anti-Mullerian Hormone Measurement in the Diagnosis of Polycystic Ovary Syndrome
Sivanandy, M. S., & Ha, S. K. (2023) · Diagnostics · doi:10.3390/diagnostics13050907 · Cited by 35
Pérez-López, F. R., Ornat, L., López-Baena, M. T., Santabárbara, J., Savirón‐Cornudella, R., & Pérez‐Roncero, G. R. (2021) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2021.03.007 · Cited by 31
“On the other hand, women with PCOS display increased circulating anti-müllerian hormone (AMH) that correlates with the number of antral follicles, and the AMH measurement diagnostic efficacy is superior to follicular count [15].”
Background
Metadata
- Authors
- Zhao, Y., Zhao, Y., Wang, C., Liang, Z., & Liu, X.
- Affiliations
- Jilin University (CN)
- Northeast Normal University (CN)
- Corresponding author
- Liu, Xin
- Venue
- Endocrine Practice
- Publisher
- Elsevier BV
- Published
- 2019-10
- Volume
- 25
- Issue
- 10
- Pages
- 1056-1066
- ISSN
- 1530-891X (ISSN-L)
- OpenAlex
- W2969054245
- Cited by
- 19
- References
- 0
- Citations by year
- 2025: 4 · 2024: 5 · 2023: 2 · 2022: 3 · 2021: 4 · 2020: 1
- FWCI
- 0.28
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Endocrine Practice (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Sexual Differentiation and Disorders
- Keywords
- syndromes, anti-Müllerian hormone, diagnostic biomarkers, diagnostic accuracy, polycystic ovary morphology, Rotterdam criteria, sensitivity and specificity, diagnostic odds ratio, PCOS diagnosis, meta-analysis update, subgroup analysis, meta-regression, heterogeneity sources, area under the receiver operating characteristic, QUADAS-2, funnel plot asymmetry, study quality assessment
- MeSH terms
- Anovulation, Female, Humans, Polycystic Ovary Syndrome, Biomarkers, Hyperandrogenism, Anti-Mullerian Hormone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Diagnostic Value of Anti-Müllerian Hormone as a Biomarker for Polycystic Ovary Syndrome: A Meta-Analysis Update. https://app.cochat.ai/papers/10.4158/ep-2019-0098
- The paper
- Zhao, Y., Zhao, Y., Wang, C., Liang, Z., & Liu, X. (2019). Diagnostic Value of Anti-Müllerian Hormone as a Biomarker for Polycystic Ovary Syndrome: A Meta-Analysis Update. Endocrine Practice. https://doi.org/10.4158/ep-2019-0098
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
